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SUMMARY 
microRNA-34a (miR-34a) and sirtuin 1 (SirT1) have been extensively studied in 
tumor biology and longevity/aging, but little is known about their functional roles in 
smooth muscle cell (SMC) differentiation from pluripotent stem cells. Using well-
established SMC differentiation models, we have demonstrated that miR-34a plays an 
important role in SMC differentiation from murine and human embryonic stem cells. 
Surprisingly, SirT1, one of the top predicted targets, was positively regulated by miR-
34a during SMC differentiation. Mechanistically, we demonstrated that miR-34a 
promoted differentiating stem cells arrest at G0/G1 phase, and observed a 
significantly decreased incorporation of miR-34a and SirT1 RNA into Ago2-RISC 
complex upon SMC differentiation. Importantly, we have identified SirT1 as a 
transcriptional activator in the regulation of SMC gene programme. Finally, our data 
showed that SirT1 modulates the enrichment of H3K9 tri-methylation around the 
SMC gene promoter regions. Taken together, our data reveal a specific regulatory 
pathway that miR-34a positively regulates its target gene SirT1 in a cellular context-
dependent and sequence specific manner, and suggest a functional role for this 
pathway in SMC differentiation from stem cells.  
 
 
Key words:  microRNAs, miR-34a, sirtuin 1, stem cells, smooth muscle cells, cell 
differentiation. 
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Introduction 
Regenerative medicine is an emerging area of multidisciplinary research in cell 
engineering and molecular biology. Its ultimate goal is to repair, replace or regenerate 
cells, tissues or organs that are lost or damaged due to disease, injury or ageing. 
Recent advances in this field have been greatly influenced by improved understanding 
of tissue engineering, stem cell biology, tissue turnover and replacement in adult 
mammals and in embryonic development. Pluripotent stem cells, including embryonic 
stem (ES) cells, have been studied extensively in regenerative medicine because of 
their distinctive capacity to self-renew and to differentiate into a wide range of 
specialized cell types, including vascular endothelial cells
1, 2
 and smooth muscle cells 
(SMCs) 
3-6
. SMC differentiation is a critical process during cardiovascular system 
formation and development, and plays a significant role in cardiovascular diseases, 
such as atherosclerosis. The understanding of the transcriptional regulatory circuitry 
of SMC differentiation is, therefore, fundamental in cardiovascular system 
development and to realize the therapeutic potential of stem cells.  However, the 
detailed molecular mechanisms of SMC differentiation from stem cells have not been 
fully clarified. 
A novel class of gene expression regulators, microRNAs (miRNAs), have been 
recently identified in almost all the species and implicated in various aspects of 
embryonic development, cellular homeostasis and disease. Traditionally, mature 
miRNAs are thought to suppress gene expression by inducing mRNA cleavage
7
 or 
mRNA decay
8
 or by inhibiting mRNA translation
9
. Strikingly, evidence has also been 
shown that miRNAs can upregulate target gene expression under specific 
circumstance
10, 11
. Interestingly, miRNAs have been suggested to play an important 
role in cell/tissue specification due to the fact that miRNAs are recognized as a 
distinct class of biological regulators with conserved functions and that many 
miRNAs are expressed in a tissue-specific manner
12
. By disrupting dicer
13
 or drosha
14
 
(both are the rate-limiting enzymes involved in the miRNA biogenesis) expression in 
ES cells, miRNAs are seen to play a role in stem cell self-renewal and differentiation. 
The significance of miRNAs in cardiovascular development has been revealed in a 
study of Dicer-deficient mice which showed that the loss of miRNAs caused severe 
impairment of heart and blood vessel development
15
. Furthermore, it has been shown 
that deletion of Dicer in vascular smooth muscle caused late embryonic lethality at 
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embryonic day 16 to 17 due to thinner vessel walls, impaired contractility and 
hemorrhage because of the decreased SMC proliferation and differentiation
16
. 
However, the significance and exact role of individual miRNAs in SMC 
differentiation remains to be elucidated. In the present study, we demonstrate for the 
first time that miR-34a plays an important role in human and murine ES cell 
differentiation towards the SMC lineage in vitro and in vivo. Unexpectedly, our data 
also reveal that miR-34a positively regulates its target gene, deacetylase sirtuin 1 
(SirT1), which is identified as a potential transcriptional activator of SMC genes. 
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Results 
miR-34a is significantly upregulated during SMC differentiation from mouse ES 
cells  
Murine ES cells were replated into collagen-coated flasks and cultured in the absence 
of leukaemia inhibitory factor (LIF) for 2 to 8 days to allow SMC differentiation as 
described previously
3-6
. As expected, SMC specific markers, such as SMαA and SM-
MHC, were expression upon cell differentiation (Figure S1). To identify potential 
miRNA candidates for SMC differentiation, total RNA including small RNA were 
harvested and subjected to miRNA microarrays analysis (Miltenyi Biotec GmbH). 
Data from the microarrays analysis revealed that, except miR-294, all other five 
members of miR-290 family, which is reported to be mouse ES cell specific miRNA 
cluster
17
, were dramatically downregulated at day 8, further confirming cell 
differentiation (Table S1). SMC differentiation related miRNAs, such as miR-143 
and 145, and cardiac/muscle miR-133, were increased in our SMC differentiation 
model, while miR-21 involved in SMC proliferation was undetectable at early stage 
of SMC differentiation (day 4) but dramatically increased at late stage of SMC 
differentiation (day 8), indicating that some miRNAs (eg. miR-143/145) may initiate 
SMC differentiation whereas others (eg. miR-21) may play important roles in the late 
stage of SMC differentiation where differentiated SMC proliferation is required to 
complete the SMC differentiation process. No significant changes were observed for 
other cell lineages specific miRNAs, such as miR-146 for T lymphocyte, miR-107 for 
monocytes, miR-203 for epidermal cell, miR-206 for myogenic cells, miR-124 for 
neural cells and miR-126 for endothelial cells (Table S1). Taken together, these 
findings confirm the specificity of SMC differentiation. Interestingly, the microarray 
analysis showed miR-34a, a reported cell cycle mediator
18
, was upregulated to a 
greater magnitude than the best known SMC differentiation related miRNAs miR-143 
and 145, during SMC differentiation, which was further confirmed by real-time RT-
PCR analysis (Figure 1A), indicating that miR-34a may play an important role in our 
SMC differentiation system.   
Important role of miR-34a in SMC differentiation from ES cells in vitro  
To investigate whether miR-34a induces SMC differentiation, gain-of-function 
experiments were conducted by using Pre-miR™ mmu-miR-34a miRNA Precursor 
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(Ambion) in differentiating ES cells. The experiments showed that miR-34a 
overexpression induced the expression of SMC-specific genes (SMA, SM22, h1-
calponin and SM-myh11) (Figure 1B). Western blot analysis revealed that there was 
also increased protein production of these genes (Figure 1C). To further test if miR-
34a expression was essential for SMC differentiation, lose-of-function experiments by 
using Anti-miR™ miR-34a inhibitoror (Ambion) were performed in differentiating 
ES cells. The study showed that knockdown of miR-34a inhibited expression of 
smooth muscle differentiation specific markers at both RNA (Figure 1D) and protein 
levels (Figure 1E). These data suggest an important role of miR-34a in SMC 
differentiation from stem cells.  
To further understand the molecular mechanism by which miR-34a regulates SMC 
differentiation, microarray analyses (Beadchip: mouseWG-6_V2_0_R3_11278593-A) 
was conducted by GENERGY Bio to examine the gene expression profiling in 
differentiating SMCs affected by miR-34a over-expression. Expectedly, data 
summarised in Table S2 showed that a panel of SMC specific genes such as CNN1, 
Acta2, Tagln2, Aebp1, Smtn, Des, Cald1, Mylk, Myh11, and Vcl (yellow-highlighted) 
were up-regulated by miR-34a over-expression. Importantly, Several SMC specific 
transcription factors including SRF, Myocd and MEF2c that were reported to be 
activated in our SMC differentiation system
3, 19
 were also significantly up-regulated 
by miR-34a, alongside SirT1 (Table S2).  Therefore, we decided to investigate if these 
factors worked in concert. Over-expression of miR-34a up-regulated SRF, myocardin 
and MEF2c, whereas knockdown of miR-34a down-regulated these genes (Figure 
S2), suggesting that miR-34a works in concert with these SMC transcription factors 
during SMC differentiation from stem cells. 
miR-34a is involved in SMC differentiation in vivo  
To facilitate our in vivo cell implantation study, miR-34a over-expressing (pLL3.7-
GFP-miR-34a) and control (pLL3.7-GFP) ES cell lines were generated by using miR-
34a over-expression (pLL3.7-GFP-miR-34a) and control (pLL3.7-GFP) lentivirus, 
respectively. GFP-positive cells with high purity (Figure S3A) were sorted out and 
maintained in ES cell culture medium. No significant differences were observed 
between the sorted cells and their parent ES cells in terms of morphology, self-renew 
and pluripotency when they were cultured in ES cell culture medium for up to five 
passages (data not shown). As expected, compared to control ES cells, the 
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expression levels of miR-34a in miR-34a overexpressing ES cells were slightly 
increased at day 0 (undifferentiated cells), but significantly up-regulated at day 8 of 
differentiation (Figure S3B), suggesting that miR-34a expression levels were 
successful up-regulated in these cells during SMC differentiation. Consequently, more 
SMCs were differentiated from miR-34a over-expressing ES cells (Figure S3C), 
further confirming a promotive role of miR-34a in SMC differentiation. To further 
explore the functional importance of miR-34a in SMC differentiation in vivo, pLL3.7-
GFP and pLL3.7-GFP-miR-34a ES cells were subcutaneously injected into C57BL/6J 
mice with 100ng/ml of PDGF-BB to promote in vivo SMC differentiation as 
described in our previous study
3, 4
. Immunofluorescence staining with antibody 
against SM-MHC showed that more SM-MHC-positive cells were presented in the 
implants of miR-34a overexpressing ES cells (Figure 2A and 2B). As expected, the 
majority of cells in the Matrigel implants were GFP-positive (green signal), indicating 
its exogenous origins (Figure 2A). Importantly, the expression levels of miR-34a, 
SMαA, SM-MHC and SirT1 in the Matrigel implants of pLL3.7-GFP-miR-34a ES 
cells were significantly higher than that of control pLL3.7-GFP ES cells as 
demonstrated by immunofluorescence staining (Figure 2A), RT-qPCR (Figure 2C) 
and western blot (Figure 2D), respectively, further confirming the efficiency of miR-
34a over-expression and the importance of miR-34a in SMC differentiation. Taken 
together, these data clearly suggest an important role of miR-34a in SMC 
differentiation from stem cells in vitro and in vivo. 
miR-34a also plays an important role in SMC differentiation from human ES cells   
To translate our finding that miR-34a plays a major regulated role in SMC 
differentiation observed from murine cell system to human, human ES cells were 
induced to differentiate towards SMCs by using a similar differentiation protocol as 
used in the mouse ES cell differentiation study. Data showed that we have 
successfully differentiated human ES cell into SMCs as demonstrated by real-time 
RT-PCR (Figure S4A), Western blot (Figure S4B), immunofluorescence staining 
(Figure S4C) and flow cytometry (Figure S4D) analyses. Along with SMC marker 
gene activation, miR-34a was significantly increased during SMC differentiation from 
human ES cells (Figure S5A), implying that miR-34a may also play a role in human 
SMC differentiation. Importantly, miR-34a over-expression (Figure S5B and S5C) 
significantly up-regulated, while miR-34a inhibition (Figure S5D and S5E) 
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dramatically down-regulated SMC marker gene expressions in differentiating human 
ES cells, further demonstrating a critical role of miR-34a in murine as well as human 
SMC differentiation. 
Target gene, SirT1, is positively regulated by miR-34a through the binding sites 
within 3’UTR   
To further investigate the mechanisms by which miR-34a regulate SMC 
differentiation, the potential mRNA targets of miR-34a were scrutinized. SirT1 was 
emerged as one of the top targets of miR-34a in several computational algorithmic 
databases, and two highly conserved binding sites for miR-34a have been identified 
within SirT1 3’UTR (Figure 3A). Unexpectedly, SirT1 gene expressions were 
significantly up-regulated (Figure 3B), and displayed a positive correlation with the 
gene expression levels of miR-34a during SMC differentiation (Figure 1A), 
suggesting that miR-34a may positively regulate this target gene, SirT1. Such notion 
has been firmly supported by the findings that SirT1 gene and protein levels were 
significantly up-regulated or down-regulated by over-expression or inhibition of miR-
34a in the differentiating ES cells (Figure 3C and 3D), respectively. These data 
indicate that SirT1 is positively regulated by miR-34a directly or indirectly. To 
confirm such possibility, the 3’UTR of SirT1 which contained the two binding sites of 
miR-34a was cloned into a luciferase reporter. Data from our miRNA reporter assay 
showed that the activity of luciferase from construct harbouring the SirT1 3’UTR was 
significantly up-regulated by miR-34a over-expression (Figure 3E). Most 
importantly, we have observed that the binding site 2 is responsible for SirT1 3’UTR 
reporter activity up-regulation mediated by miR-34a by using site-directed 
mutagenesis of the predicted individual binding site or all two binding sites for miR-
34a in the SirT1 3’UTR reporter (Figure 3E). Altogether, above data has firmly 
confirmed that SirT1 is a true mRNA target of miR-34a, which is positively regulated 
by miR-34a during SMC differentiation. 
miR-34a differently regulates SirT1 gene expression in ES cells and terminally 
differentiated  SMCs   
To investigate if the observed phenomena that miR-34a directly up-regulated its target 
gene, SirT1, expression during SMC differentiation is cellular context specific, we 
conducted miR-34a over-expression or inhibition experiments and luciferase activity 
assays in naïve stem cells (undifferentiated ES cells) and terminally differentiated 
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SMCs (we previously reported that day 8 differentiated SMCs are fully/terminally 
differentiated SMCs
19
), respectively. Data showed that SirT1 3’UTR reporter activity 
was significantly down-regulated by miR-34a over-expression, but up-regulated by 
miR-34a inhibition at naïve stem cell stage (Figure 4A). As expected, SirT1 gene 
expression was significantly increased by over-expression of miR-34a, while 
decreased by miR-34a knockdown (Figure 4B), suggesting that miR-34a regulates 
SirT1 gene expression is cellular context dependent. In the previous section, we have 
successful demonstrated the miR-34a bindings sites are required for miR-34a 
mediated SirT1 gene regulation (Figure 3E). We further wondered if the miR-34a 
binding site is sufficient for miR-34a mediated SirT1 gene expression. To this aim, 
we constructed a luciferase reporter with an artificial miR-34a binding site on its 
3'UTR, without surrounding RNA sequence and structure of SirT1 3`UTR, designated 
as pmiR-Luc-miR-34a binding site, and performed luciferase activity assay. We found 
that miR-34a slightly up-regulated this reporter activity, but could not reach 
significance (Figure 4C), indicating that the surrounding RNA sequence and/or 
structure of SirT1 3’UTR is also required for miR-34a mediated SirT1 gene up-
regulation.  
We have previously reported miR-200c mediates endothelial cell differentiation by 
targeting transcription factor ZEB1
20
 which contains no miR-34a binding site within 
3’UTR. Expectedly, we observed no effects of miR-34a over-expression on ZEB1 
gene reporter activity (a non-miR-34a target) (Figure S6A), confirming that miR-34a 
specifically up-regulates SirT1 gene expression during SMC differentiation. To 
further distinguish if our observation that up-regulation of SirT1 by miR-34a during 
SMC differentiation is a universal phenomenon or a specific event, two additional 
experiments were conducted. We first performed luciferase assays with the non-miR-
34a reporter (pmiR-Luc-ZEB1) in conjunction with miR-200c over-expression in 
naïve stem cells and terminally differentiated SMCs, respectively. We found that 
miR-200c negatively regulated ZEB1 gene reporter activity in both cells (Figure S6B 
and S6C), which is consistent with our previous observation in endothelial cell 
differentiation. Moreover, it is well-known that 12-O-tetra-decanoylphorbol-13-
acetate (TPA) can induce monocyte differentiation through regulating cell cycle 
progression. We then applied this model to investigate if up-regulation of SirT1 by 
miR-34a may (or may not) be specific to differentiating stem cells. While miR-34a 
expression levels were clearly up-regulated by TPA during monocytes differentiation, 
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no significant changes in terms of SirT1 expression levels were observed during the 
same process (Figure S6D), implying no significant involvement of miR-34a in 
regulation of SirT1 gene expression in this monocyte differentiation model. Taken 
together, above data clearly suggests that up-regulation of SirT1 by miR-34a during 
SMC differentiation from ES cells is a specific event which is likely dependent on 
specific cellular context, miRNA binding sites and surrounding sequence, and/or other 
RNA binding proteins. 
Less miR-34a and SirT1 mRNA were incorporated into Ago 2-RISC complex upon 
differentiation  
To further investigate the molecular mechanism by which miR-34a up-regulates SirT1 
gene expression upon SMC differentiation, we conducted the RNA-IP assays with 
Ago 2 antibody in both undifferentiated stem cells and differentiated SMCs. 
Expectedly, no significant difference in terms of Ago 2 protein levels between 
undifferentiated ES cells and differentiated SMCs was observed (Input samples, 
Figure 4D), and the immunoprecipitation efficiencies in both cells are comparable 
(Ago2-IP and IgG-IP samples, Figure 4D). Moreover, compared to IgG control, 
Ago2 antibody could specifically pull-down miR-34a as well as SirT1 RNA with 
mean enrichment folds of 26 v.s 2.1 (ESCs v.s dSMCs) for miR-34a, 16.4 v.s 3.94 for 
SirT1 3’UTR around binding site 1, and 26.5 v.s 2.1 for binding site 2, respectively 
(Figure 4F). Importantly, the enrichment levels of miR-34a and SirT1 3’UTR RNA 
(spanning around miR-34a binding sites 1 and 2) in undifferentiated stem cells (ESCs) 
were much higher than that of differentiated SMCs (dSMCs) (Figure 4E), indicating 
that much less miR-34a and SirT1 3’UTR were loaded into Ago 2 RISC complex 
upon SMC differentiation. 
miR-34a promotes cell cycle arrest at G0/1 in differentiating ES cells 
Several elegant studies conducted by Joan A. Steitz and colleagues have famously 
revealed that the miRNA-target gene regulatory machinery will switch from 
translation repression to activation when the cells have been arrested at G0/1 phase
10
 
and miRNAs can regulate target gene translation activation in quiescent cells
11
. We 
therefore wondered if the differentiating cells underwent such cell cycle arrest. As 
expected, cell cycle analyses revealed that differentiating cells were gradually arrested 
at G0/1 phase during SMC differentiation (Figure S7A). Importantly, such arrest has 
been significantly reinforced by miR-34a over-expression (Figure S7B). Moreover, 
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data from apoptosis analysis and BrdU incorporation assays showed that miR-34a 
plays no significant role in cell apoptosis and death (Figure S7C), while much less 
cells were entering S-phase upon miR-34a over-expression (Figure S7D). Taken 
together, these data suggests that the promotive effects of miR-34a on cell cycle arrest 
at G0/1 is, at least partially, responsible for the SirT1 gene up-regulation by miR-34a 
during SMC differentiation. To further confirm if miR-34a up-regulates SirT1 gene 
expression is specific to G0/G1 cell cycle stage, differentiating SMCs were arrested at 
G0/G1 phase by cell cycle arrest inducer aphidicolin
10
 and luciferase activity assays 
were conducted. As expected, incubation of differentiating SMCs with 2µg/ml 
aphidicolin for 24 to 28 hours significantly increased cells arrest at G0/G1 stage, 
which was further increased in the presence of miR-34a over-expression (Figure 
S7E). Consequently, SirT1 3’UTR reporter activity was significantly up-regulated by 
aphidicolin and miR-34a over-expression in a similar manner (Figure S7F). 
SirT1 activation is required for miR-34a mediated SMC gene expressions 
We have demonstrated nicely that SirT1 is the mRNA target of miR-34a during SMC 
differentiation. To investigate the potential role of SirT1 in SMC differentiation, 
SirT1 over-expression in the differentiating ES cells was conducted by using SirT1 
over-expression plasmid (pcDNA3.1-SirT1
21
, a kind gift from Dr. Hang Shi, Wake 
Forest University School of Medicine, North Carolina, USA). Data showed that over-
expression of SirT1 significantly up-regulated SMC specific marker expressions 
(Figure 5A and 5B), suggesting that SirT1 over-expression can recapitulate the 
effects of miR-34a during SMC differentiation from ES cells. We further 
hypothesised that SirT1 activity is required for miR-34a mediated SMC 
differentiation. To test this, control (pLL3.7-GFP) or miR-34a over-expressing 
(pLL3.7-GFP-miR-34a) ES cells were induced to differentiate into SMCs for 4 days 
in the absence or presence of SirT1 specific inhibitor. Data shown in Figure 5C 
revealed that while SirT1 inhibition (2
nd
 columns) or miR-34a over-expression (3
rd
 
columns) alone in the differentiating ES cells were significantly down-regulated or 
up-regulated various SMC specific gene expression, respectively, inhibition of SirT1 
almost completely abolished SMC specific gene up-regulations induced by miR-34a 
over-expression (4
th
 columns). Such observation was further confirmed in SirT1 
knockdown experiments by using SirT1 specific siRNA (Figure 5D), suggesting that 
miR-34a regulates SMC gene expression during SMC differentiation from ES cells 
through activation of SirT1. It has been reported that SirT-1 agonist resveratrol 
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promotes osteogenic differentiation of mesenchymal stem cells
22, 23
. Consistently, our 
data revealed that resveratrol also significantly increased SMC specific gene 
expression with the best concentration of 5µM (Figure 5E), further supporting a role 
of SirT1 activation in SMC differentiation.  
SRF binding site is required for SirT1 mediated SMC gene expression 
SirT1 has been shown to up-regulate SMC specific gene expression. To investigate if 
SirT1 over-expression will activate the specific SMC gene transcription, luciferase 
activity assays were conducted in differentiating ES cells. The reporter gene plasmids 
used in the luciferase assay, pGL3-Luc-SMαA and pGL3-Luc-SM22α, were 
previously designed and cloned in our previous study
24
. Data shown in Figure 6A 
revealed that the overexpression of SirT1 in differentiating ES cells significantly 
increased SMαA and SM22α gene promoter activities, indicating that SirT1 over-
expression can activate specific SMC gene promoters. It has been well-known that 
SRF binding element (CArG) within promoter region of SMC genes is required for 
transcriptional activation of SMC genes
25
, we thus wondered if this is also a case for 
SirT1-regulated SMC gene transcriptional activation. To this aim, another set of 
luciferase assays using SRF binding site mutants (pGL3-Luc-SMαA-SRFmu and 
pGL3-Luc-SM22α-SRFmu) generated in our previous study3 were carried out in 
differentiating ES cells. Data showed that SRF binding element mutation in pGL3-
Luc-SMαA and pGL3-Luc-SM22α resulted in complete lost of their transcriptional 
activity in response to SirT1 over-expression (Figure 6A), suggesting that SirT1 
regulates SMC differentiation gene expression through SRF binding site within the 
promoters. Moreover, ChIP assays were conducted using SirT1 antibody in the 
differentiating ES cells to further verify if SirT1 activates specific SMC gene 
transcription through direct binding to their promoters. Data shown in Figure 6B 
revealed that SirT1 directly bound to the region spanning around SRF binding 
element (CArG) of SMαA and SM22α gene promoters, and such binding was 
dramatically enhanced by SirT1 over-expression. Finally, CHIP assay data also 
showed that the binding capacity of SRF to SMαA and SM22α gene promoters was 
significantly enhanced by SirT1 over-expression (Figure 6C). Taken together, above 
findings demonstrate for the first time that SirT1 regulates SMC specific gene 
expressions during SMC differentiation through direct binding to the promoter region 
of SMαA and SM22α genes and increasing the binding ability of SRF to SMC 
specific gene promoters.  
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SMC transcription factors are transcriptionally regulated by SirT1 
SRF, MEF2c and myocardin are well-known transcription factors for regulating SMC 
gene expression and play important roles in cardiovascular system development. Data 
shown in Figure 7A revealed that gene expression levels of all three factors were 
significantly regulated by SirT1 over-expression, suggesting SirT1 may have a direct 
role in regulation of these transcription factors during SMC differentiation. To 
confirm such possibility, luciferase activity assays by using SRF, MEF2c and Myocd 
gene reporter plasmids (pGL3 -Luc-SRF, pGL3 -Luc-MEF2c and pGL3 -Luc-Myocd) 
generated in our previous study
3
 were conducted in the differentiating ES cells. Data 
showed that the SirT1 over-expression significantly increased SRF, MEF2c or Myocd 
gene promoter activities (Figure 7B), indicating that SirT1 may activate 
transcriptional activity of these three genes. To further investigate if SirT1 can 
directly bind to the promoters of SRF, MEF2c and Myocd, and its potential binding 
region(s) of SirT1 within these three gene promoters, CHIP assays with SirT1 
antibody were conducted and two pairs of primers for each gene were used to amplify 
target DNA. A set of specific primers (4 pairs) spanning through the respective 
promoter regions of SRF, MEF2c and Myocd as described in our previous study
3
 
were used in our preliminary study and the best primer pairs were chosen to use in the 
following experiments. Data shown in Figure 7C revealed that SirT1 directly binds 
to the promoter regions between -1393 and -1274 of SRF gene, -1335 and -1263 of 
MEF2c gene or -708 and -620 of Myocd gene, respectively, and such binding activity 
was significantly enhanced by SirT1 over-expression. Taken together, these findings 
strongly imply that SirT1 transcriptionally regulates SMC transcription factor gene 
expression during SMC differentiation from stem cells.  
SirT1 promotes SMC gene expression through inhibiting H3K9 methylation around 
SMC gene promoters 
DNA and/or histone methylation is an important gene transcription regulator, and has 
been implicated in enormous cellular functions and various diseases. It is well-known 
that methylation of lysines H3K9 and H3K27 is closely associated with 
transcriptional repression
26
. To investigate if SirT1 affects H3K9me3 expression 
levels during SMC differentiation, SirT1 over-expression experiments were 
conducted in differentiating ES cells. Data showed that H3K9me3 protein expression 
levels were not regulated by SirT1 over-expression (Figure S8A), however their 
enrichments on SMαA and SM22α gene promoters were significantly inhibited by 
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over-expression of SirT1 (Figure S8B), suggesting that SirT1 regulates SMC-specific 
gene activation, at least partially through inhibiting H3K9 tri-methylation around 
SMC specific gene promoters.  
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Discussion 
SMC differentiation from pluripotent stem cells is a complicated and poorly defined 
process triggered by a variety of stimulation, such as growth factors, extracellular 
matrix, mechanical stress and micro-environmental milieu, and governed by various 
molecular signal pathways. Despite enormous efforts have been put into this field in 
the past decade, our understandings into the molecular mechanisms underlying SMC 
differentiation are still far from complete. In the present study, we have advanced our 
knowledge of the molecular mechanism mediating SMC differentiation by uncovering 
an important role of miR-34a in regulating SMC specific gene expression and SMC 
differentiation from murine ES cells in vitro and in vivo. Such importance of miR-34a 
has also been confirmed in human SMC differentiation from stem cells. Surprisingly, 
we have identified SirT1 as the mRNA target of miR-34a, and demonstrated that miR-
34a positively regulates its target gene, SirT1, during SMC differentiation. 
Mechanistically, we have found that miR-34a promotes cell cycle arrest at G0/1 phase, 
and observed a significant decreased incorporation of miR-34a and SirT1 RNA into 
Ago2-RISC complex upon SMC differentiation. We have also clearly defined that 
SirT1 is a potential transcription activator of SMC-specific gene regulation. Moreover, 
our data also revealed that the SRF binding site(s) within SMC specific gene 
promoters is required for SirT1 mediated SMC gene transcriptional activation, and 
SirT1 regulates SMC transcription factors (SRF, MEF2c and Myocd) at transcriptional 
level. Finally, we have observed that SirT1 regulates SMC gene expression through 
modulating the histone methylation status around SMC-specific gene promoters. 
Taken together, data provided in the current study strongly suggests that miR-34a is a 
powerful SMC differentiation modulator by positive regulating its target gene, SirT1, 
a molecule functioning as a potential SMC-specific gene transcriptional activator.  
miR-34a and SMC differentiation 
In mammalians, the miR-34 family comprises three processed miRNAs that are 
encoded by two different genes: miR-34a is encoded by its own transcript, and miR-
34b and miR-34c share a common primary transcript
27
. In 2007, several laboratories 
independently reported that members of the miR-34 family are direct p53 targets, and 
their upregulation induces apoptosis and cell-cycle arrest
18, 28, 29
.  Strikingly, the most 
highly enriched gene ontology category among the upregulated transcripts induced by 
miR-34a overexpression was ‘‘cell cycle’’28, which strongly indicates that miR-34a is 
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a major player in the regulation of cell cycle progression.  Considering cell cycle 
arrest or exiting from cell cycle progression is a critical process during cell 
differentiation, miR-34a could be a major regulator in cell differentiation from stem 
cells. In addition, similar to other p53-target genes, miR-34a may be an important 
regulator for other signalling pathways involved in normal embryos development, cell 
differentiation, apoptosis, senescence, proliferation and various diseases including 
cancer and cardiovascular diseases. Importantly, it has been recently reported that 
suppression of somatic cell reprogramming into pluripotent cells by miR-34a was due, 
at least in part, to repression of pluripotency genes, including Nanog, Sox2 and N-
Myc
30
, which strongly suggests that miR-34a could play an important role in stem cell 
differentiation. Evidently, recent studies have suggested an important role of miR-34a 
in neural differentiation from neural stem cells
31
 and megakaryocytic differentiation 
from bipotent K562 human leukemia cells
32
. miR-34a has also been identified as a 
critical cell-fate determinant in early-stage dividing colon cancer stem cells
33
. 
However, the functional role of miR-34a in SMC differentiation remains to be 
explored. By using our well-established SMC differentiation system and miRNA 
array technique, miR-34a was emerged as a top potential miRNA candidate to 
regulate SMC differentiation. By utilizing miRNA gain/lose-of function analyses, we 
confirmed a critical role of miR-34a in SMC differentiation from murine and human 
ES cells in vitro. Furthermore, we also provide clear evidence to support that miR-34a 
plays an important role in embryonic SMC differentiation in vivo by generating miR-
34a over-expressing ES cell lines and using another well-established in vivo Martigel 
implantation model. These observations clearly implied that miR-34a is a SMC 
differentiation regulator. 
Up-regulation of SirT1 by miR-34a during SMC differentiation is a specific 
event which likely dependent on specific cellular context, miRNA binding sites 
and surrounding sequence, and/or the interactions between RNA binding 
proteins and 3’UTR of SirT1 gene 
It has been suggested that miR-34a regulates cell cycle progress and apoptosis in 
cancer cells by repressing its target gene SirT1 and forming a double positive 
feedback loop to regulate p53 activity
34, 35
.  Surprisingly, we have provided clear and 
solid evidence to suggest that rather than translational repression, miR-34a regulates 
SirT1 in a translational activation manner. However, it is noteworthy to point out that 
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the up-regulation of SirT1 expression by miR-34a during SMC differentiation from 
ES cells is representing a specific event between miR-34a and SirT1 in our SMC 
differentiation model, which is likely dependent on specific cellular context, miRNA 
binding sites and surrounding sequence, and/or other RNA binding proteins. Such 
notion has been supported by several lines of evidence: Firstly, SirT1 gene expression 
was significantly activated during SMC differentiation from stem cells (Figure 3B). 
Secondly, SirT1 gene and protein expression levels were positively regulated by miR-
34a expression levels as demonstrated in miR-34a over-expression and inhibition 
experiments (Figure 3C and D). Thirdly, over-expression of miR-34a significantly 
up-regulates SirT1 3’UTR activity, but such up-regulation was completely abolished 
when the miR-34a binging sites were mutated (Figure 3E). Fourthly, the luciferase 
activity of other 3’UTR reporters, which containing the binding site(s) of unrelated 
miRNAs, but not of miR-34a, were not regulated by miR-34a (Figure S6A). Fifthly, 
SirT1 gene expression levels in the Matrigel implants with miR-34a over-expressing 
ES cells were much higher than that of the Matrigel plugs implanted with control ES 
cells (Figure 2C and 2D), suggesting SirT1 gene expression level is also positively 
associated with miR-34a expression level during in vivo SMC differentiation from 
stem cells. Finally but importantly, we observed a negative regulatory relationship 
between a non-miR-34a reporter (pmiR-luc-ZEB1) and its corresponding miRNA 
(miR-200c) (Figure S6B and S6C). The unexpected but novel finding by which miR-
34a positively regulates SirT1 could be explained by the following facts and/or 
observations: 1) Differentiating ES cells undergo cell cycle arrest at G0/1 phase and 
miR-34a promotes cell cycle arrest at G0/1 phase (Figure S7A and S7B). As 
mentioned early, the miRNA-target gene regulatory machinery will switch from 
translation repression to activation when the cells have been arrested at G0/1 phase
10
 
and locked in quiescent cells
11
. Therefore, our findings that miR-34a positively 
regulates target gene SirT1 during SMC differentiation is consistent with their data. 2) 
Another suggested criteria by the study
10
 for miRNAs up-regulate their target genes is 
the AU rich elements existing within 3’UTR. By using free online search tool 
(http://rna.tbi.univie.ac.at/cgi-bin/AREsite.cgi), similar to TNF-α we have found 
that SirT1 3’UTR is an A/U rich sequence (67%), and identified nearly 11 AU rich 
elements (ARE) sites within 3’UTR of SirT1 (spanning through 1000bps). Most 
importantly, we have also found the miR-34a binding site 2 is located closely with 8 
of 11 ARE sites within SirT1 3’UTR (Figure S9). 3) miR-34a negatively regulates 
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SirT1 gene expression in undifferentiated ES cells, while positively regulates SirT1 
gene expression in the terminally differentiated SMCs (Figure 4A and 4B). 4) We 
observed that G0/G1 cell cycle arrest inducer aphidicolin could up-regulate SirT1 
gene reporter activity, and a synergetic effect between aphidicolin and miR-34a over-
expression on SirT1 gene regulation (Figure S7F). 5) Removal of surrounding RNA 
sequence and structure of SirT1 3’UTR almost abolished the up-regulative effects of 
miR-34a on SirT1 3’UTR reporter activity (Figure 4C). All these observations have 
provided a strong indication that miR-34a may positively regulate SirT1 gene 
expression through their binding sites within 3’UTR, which has been nicely proven by 
our finding that miR-34a binding site 2, rather than binding site 1, is required for 
miR-34a mediated SirT1 gene up-regulation (Figure 3E). Our data also clearly 
suggests that up-regulation of SirT1 by miR-34a during SMC differentiation is a 
specific event (G0/G1 cell cycle arrest) between miR-34a and SirT1 gene during SMC 
differentiation, and both miR-34a binging sites and surrounding RNA 
sequence/structures within 3’UTR of SirT1 gene are required for such an event. 
Evidently, data from other studies also suggests that miRNAs can up-regulate their 
target genes in other cell systems under normal cell culture condition. It have been 
reported that miR-155 directly and indirectly enhances its target gene TNF-α 
translation in macrophages
36
, and miR-744 up-regulates ccnB1 through the binding 
sites within gene promoter region in NIH/3T3 fibroblasts as well as  TRAMP C1 
cells
37
. Additionally, miRNAs have also been suggested to up-regulate their target 
genes in immature oocytes
38
. 
It has been well-documented in the literature that various RNA-binding proteins 
(RBPs) play a crucial role in modulating miRNA function. An elegant study 
conducted by Kundu and colleagues has nicely demonstrated that RNA-binding 
protein HuR attenuates miRNA-mediated repression by promoting miRISC 
dissociation from the target RNA
39
. Moreover, our previous studies have suggested an 
important role for another two RBPs, hnRNPA1
3
 and hnRNPA2B1
40
, in SMC 
differentiation from stem cells. Importantly, our data shown in figure 4C suggested 
that miR-34a mediates SirT1 up-regulation during SMC differentiation in a sequence 
dependent manner. Together with our another observation that much less miR-34a 
and SirT1 3’UTR were loaded into Ago 2 RISC complex upon SMC differentiation 
(Figure 4 E), which prompt us to speculate that miR-34a positively regulates its 
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target gene SirT1 during SMC differentiation through a similar mechanism as 
reported by Kundu and colleagues. In other words, the up-regulation of SirT1 by miR-
34a may well be a result of RBPs, such as HuR, hnRNPA1 and hnRNPA2B1, 
interacting with miR-34a binding sites and/or other elements within the 3'UTR of 
SirT1 to disengage it from Ago2-RISC complex during differentiation. Although it 
warrants for further studying, investigations into confirming such a possibility is 
outside the current remit of this study.  
SirT1 regulates SMC differentiation gene expression through a transcriptional 
mechanism  
One of novel mechanistic findings in the present study is that we provided clear 
evidence to support that SirT1 regulates SMC differentiation gene expression through 
a transcriptional mechanism. SirT1 is a member of the a NAD+-dependent class III 
group of histone deacetylases, and has been reported to be involved in a variety of 
biological systems and cellular functions, including obesity-associated metabolic 
diseases, cancer, aging, cellular senescence, cardiac aging and stress, prion-mediated 
neurodegeneration, inflammation, and placental cell survival
41
. Importantly, recent 
data also suggests that SirT1 is a critical mediator in regulation of various 
development genes during stem cell differentiation
42
, and plays an important role in 
various cellular differentiations including endothelial progenitor cells
43
, 
hematopoietic cells
44
, and osteoblasts
45
.  In the present study, we have provided clear 
evidence that SirT1 is an important SMC differentiation mediator by transcriptional 
regulation of SMC specific genes and transcriptional factors. Traditionally, SirT1 has 
mainly been linked to negative regulation of gene expression through deacetylation of 
histone and non-histone proteins
46
, however, accumulating evidence also strongly 
suggests that SirT1 can act both positively and negatively to control gene expression 
by recruiting a different set of coactivators and corepressors such as peroxisome 
proliferator–activated receptor γ coactivator-1α47 or via a transcriptional mechanism48. 
In response to stress, activated SirT1 transcriptionally regulates its downstream target 
genes such as transcriptional factors (forkhead box Os and hypoxia-inducible factors-
2α) and cardiac α-myosin heavy chain, through which SirT1 exerts a cardioprection 
response
41
. In consistent with these findings, we have provided strong evidence in the 
current study which firmly demonstrated that SirT1 is a transcription activator in 
regulation of SMC-specific gene expression (SMαA, SM22α, SRF, MEF2c and myocd) 
during SMC differentiation (Figure 6A and 7B). Direct evidence for such 
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transcriptional regulation of SMC specific genes was obtained from CHIP assays 
(Figure 6B and 7C), in which our data revealed that SirT1 can directly bind to the 
promoter DNA of SMC-specific genes and transcription factors.  
Another important finding of the present study is that we further demonstrate that 
SirT1 acts as a potential transcriptional regulator for SMC gene regulation through 
modulating epigenetic modifications. It has been reported that SirT1 can induce the 
production of H3K9me3 in cultured U2OS cells
49
 through directly interacting with 
and deacetylating histone methyltransferase SUV39H1
50
. Our previous data also 
suggests that H3K9 methylation was enriched within SMC specific gene promoter 
regions in the differentiating stem cells
5
. Data in the current study supports a notion 
that instead of inducing H3K9me production, SirT1 represses H3K9 tri-methylation 
status within SMC-specific gene promoters, resulting in SMC gene activation. 
However, the functional involvements of SirT1 in the regulation of other epigenetic 
modifications remain to be fully elucidated.  
Taken together, we have successful uncovered a novel role of miR-34a in SMC 
differentiation from stem cells in vitro and in vivo, and provided compelling evidence 
to support our unexpected finding that miR-34a positively regulates its target gene 
SirT1 during SMC differentiation. Moreover, our data also suggests that the miRNA-
target gene regulatory machinery should be carefully considered under certain 
circumstance. Furthermore, we have revealed that SirT1 regulates SMC gene 
expression through a transcriptional mechanism as well as an epigenetic signal 
pathway. However, it is noteworthy to mention that although we have provided some 
direct and strong evidence to show that SirT1 regulates SMC-specific transcription 
factor gene transcriptional activity through direct binding to the promoter regions of 
these genes (SRF, Myocd and MEF2c) (Figure 7), the minimal essential binding 
elements of SirT1 or exactly SirT1 binding motifs within these gene promoter regions 
remains to be further identified in our future study. Nevertheless, our findings will 
significantly increase our understanding of the molecular mechanisms in SMC 
differentiation and benefit future application in regenerative medicine. 
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Materials and Methods 
ES cell culture and smooth muscle cell (SMC) differentiation. Detailed protocols 
for mouse embryonic stem cells (mESCs) (ES-D3 cell line, CRL-1934; ATCC, 
Manassas, USA) culture and SMC differentiation were described in our previous 
studies
3-6, 19, 24, 40, 51, 52
. The Shef-1, 2, 3, 6 and 7 human embryonic stem (ES) cell 
lines were obtained from the United Kingdom Stem Cell Bank (UKSCB, 
Hertfordshire, UK) and maintained in our Laboratory as described in our previous 
study
20
. Briefly, undifferentiated ES cells were dissociated into single cells and 
seeded onto collagen I/IV (5μg/ml)-coated flasks or plates in differentiation medium 
[DM, MEM alpha medium (Gibco) supplemented with 10% FBS, 0.05mM 2-
mercaptoethanol, 100 U/ml penicillin, and 100 μg/ml streptomycin] for 0 to 9 days 
prior to further treatment. The medium was refreshed every other day. In our 
preliminary studies, we observed that there were no significant differences in terms of 
SMC differentiation capacity among these cell lines, but the Shef-3 cell line was the 
best to grow and scale-up. Therefore, Shef-3 cell line was routinely maintained in our 
laboratory and used in the current study.  
microRNA and plasmids transfection. Either miRNAs inhibitors or precursors and 
miRNA negative controls (30nM) were transfected into differentiating ES cells using 
siPORT
TM
 NeoFX
TM
 transfection agent (Ambion, Applied Biosystems) according to 
the manufacturer's instructions. Transfected cells were plated into flasks or plates 
coated with 5μg/ml of collagen and cultured for 48~72 hours in the SMC 
differentiation medium to allow SMC differentiation. All miRNAs inhibitors or 
precursors and respective negative controls were purchased from Ambion. Control 
(pcDNA3.1) and SirT1 overexpression (pcDNA3.1-SirT1
21
, a kind gift from Dr. Hang 
Shi, Wake Forest University School of Medicine, North Carolina, USA) plasmids 
were transfected into differentiating ES cells using Fugene-6 (Roche) according to the 
manufacturer's instructions. 
SirT 3’UTR clone and miR-34a binding sites mutation. Reporter vector harbouring 
sequences of the murine SirT1 was created using cDNA from differentiating ES cells. 
The 3’-flanking untranslation region (2306bp/3636bp) of murine SirT1 gene 
(NM_019812.2) was amplified by PCR with primers shown in Table S3 and cloned 
into the Mlu I and Sac I sites of the pmiR-reporter-basic vector (Ambion, Applied 
Biosystems), designated as pmiR-Luc-SirT1-WT. miR-34a binding site 1, 2 mutation 
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alone or combination were introduced into pmiR-Luc-SirT1 by using QuikChange™ 
site-directed mutagenesis kit (Agilent Technologies) according to the manufacturer's 
instructions. These were designated as pmiR-Luc-SirT1-BS1
mu
, pmiR-Luc-SirT1-
BS2
mu
, and pmiR-Luc-SirT1-BS1/2
mu
 mutants, respectively. An artificial miR-34a 
binding site was introduced into pmiR-Luc by using PCR based QuikChange™ site-
directed mutagenesis, designated as pmiR-Luc-miR-34a binding site. All vectors were 
verified by DNA sequencing. 
Statistical analysis. Data were expressed as mean±SEM and analyzed using a two-
tailed student’s t-test for two-group comparision or one-way ANOVA followed by 
Tukey’s HSD multiple comparison post-hoc test for comparing different groups. A 
value of P < 0.05 was considered as statistically significant. 
 
A detailed description on the expanded materials and methods is provided in the 
Online Supporting Information.  
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Figure Legend 
Figure 1. Important role of miR-34a in SMC differentiation from ES cells.  
(A) miR-34a was up-regulated during SMC differentiation from ES cells. Day 0 
samples were undifferentiated ES cells and served as negative control. (B-C) miR-34a 
overexpression significantly increases SMC marker expressions. ES cells were 
transfected with miR-34a precursor or miR precursor negative control, and cultured in 
SMC differentiation medium for 48~72 hours. miR-145 precursor in (C) was included 
as positive control. (D-E) miR-34a inhibition reduces SMC marker expressions. Day 
3 differentiating ES cells were transfected with miR-34a inhibitor or miR inhibitor 
negative control, and cultured in SMC differentiation medium for 48 hours. miR-145 
inhibitor in (D-E) was included as positive control. The data presented here are 
representative or mean±S.E.M. of three to six independent experiments. *P<0.05.  
Figure 2. miR-34a promotes SMC differentiation in vivo.  
Matrigel plugs implanted with ES cells without (pLL3.7-GFP) or with (pLL3.7-GFP-
miR-34a) miR-34a over-expression were harvested, sectioned and subjected to 
immunofluorescence staining using antibodies against GFP and SM-MHC, or SirT1 
alone. Representative images (A) and quantitative data (B) of the percentage of SM-
MHC-positive cells were presented here, respectively. Note: cells with green 
fluorescence signal indicate GFP-positive cells (implanted cells) within Matrigel 
plugs. The percentage of GFP-labelled SM-MHC-positive cells per field were 
examined by two well-trained independent investigators blinded to the treatments, 
from four random high power fields (200x) in each section, three sections from each 
implant and four implants for each group, *p<0.05. (C-D) Gene expression levels 
within Matrigel implants. Total RNA and protein samples were extracted from partial 
Matrigel implants and subjected to RT-qPCR (C) and western blot (D) analysis, 
respectively. The data presented here are representative or mean±S.E.M. of four 
Matrigel implants. *P<0.05.  
Figure 3. Target gene, SirT1, is positively regulated by miR-34a through the 
binding sites within 3’UTR.  
(A) The potential binding sites of miR-34a within SirT1 3’UTR as predicted by 
Targetscan are depicted in this illustration. (B) SirT1 was up-regulated during SMC 
differentiation from ES cells. (C and D) Modulations of miR-34a expression levels 
positive regulate SirT1. (E) miR-34a binding site 2 is required for miR-34a mediated 
SirT1 gene activation. miR-34a precursor or negative control and wild type SirT1 
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3’UTR reporter (pmiR-Luc-SirT1-WT) or three mutants [bindings site 1 (BS1mu), 2 
(BS2
mu
), and combinational mutations (BS1/2
mu
)] were co-transfected into day 2~3 
differentiating ES cells and luciferase activity assay were measured at 48 hours post-
transfection. The data presented here are representative or mean±S.E.M. of three to 
four independent experiments. *P<0.05 (treatment versus day 0 or control), #P<0.05 
in (E) (binding site mutants versus wild type).  
Figure 4. miR-34a differently regulates SirT1 gene expression in ES cells and 
terminally differentiated  SMCs   
(A) miR-34a negatively regulates SirT1 expression in naive stem cell stage. 
Undifferentiated ES cells were co-transfected with control miRNAs, miR-34a 
precursor or miR-34a inhibitor and pmiR-Luc-SirT1, respectively. Luciferase activity 
assay were measured at 48 hours post-transfection. (B) miR-34a positively regulates 
SirT1 expression in terminally differentiated stage. Day 8 differentiated SMCs were 
co-transfected with control miRNAs, miR-34a precursor or miR-34a inhibitor and 
pmiR-Luc-SirT1, respectively. Luciferase activity assay were measured at 48 hours 
post-transfection. (C) Surrounding structure(s) or sequences of SirT1 3’UTR is 
required for miR-34a mediated SirT1 gene up-regulation. (D) Ago2 protein levels and 
IP efficiency. The expression levels of Ago2 (input) and RNA-IP efficiencies (Ago2-
IP and IgG-IP) in undifferentiated ES cells (ESCs) and differentiated SMCs (dSMCs) 
were examined using Ago2 antibody. (E) Less miR-34a and SirT1 mRNA were 
incorporated into Ago2-RISC complex upon differentiation. Undifferentiated ES cells 
and differentiated SMCs were harvested and subjected to RNA-IP assay. RNA-IP 
assays were performed using antibodies against Ago2, or normal rabbit IgG, 
respectively, as described in online supplemental data. RT-qPCR amplification of the 
SirT1 coding region was included as additional control for specific SirT1 3’UTR 
enrichment. Dash line in (E) indicates the enrichment level for IgG control which was 
set as 1.0. The data presented here are representative or mean±S.E.M. of three to four 
independent experiments. *P<0.05 (vs. control).  
Figure 5. SirT1 activation is required for miR-34a mediated SMC gene 
expressions.  
(A-B) Over-expression of SirT1 up-regulated SMC gene expressions. Day 2~3 
differentiating ES cells were transfected with control (pcDNA3.1) or SirT1 over-
expression plasmid (pcDNA3.1-SirT1), and cultured in SMC differentiation medium 
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for another 48 or 72 hours. The data presented here are representative or mean±
S.E.M. of three independent experiments, *P<0.05. (C) SirT1 inhibition abolished 
SMC gene expression increased by miR-34a over-expression. Control (pLL3.7-GFP) 
and miR-34a over-expressing (pLL3.7-GFP-miR-34a) ES cells were induced to 
differentiate into SMCs for 4 days and SirT1 specific inhibitor III (500nM, EMD 
Millipore, 566322) or control vehicle were added into the culture medium for 6 or 12 
hours before harvest. (D) SirT1 knockdown abrogated the effects of miR-34a over-
expression on SMC gene expression. Day 2~3 differentiating ES cells were co-
transfected with miR-34a precursor, SirT1 siRNAs or respective control (miRNA 
precursor negative control and siRNA control) as indicated, and cultured in SMC 
differentiation medium for another 48 hours. (E) SirT-1 agonist resveratrol promotes 
SMC gene expression. The data presented here are mean±S.E.M. of three or four 
independent experiments. *P<0.05 (versus related controls); #P<0.05 (4
th
 bars versus 
3
rd
 bars). 
Figure 6. SRF binding site is required for SirT1 mediated SMC gene expression.  
(A) SRF binding site mutation abolished SMC differentiation gene promoter activity 
induced by SirT1 overexpression. (B) SirT1 binds directly to the promoter regions of 
SMC differentiation genes. (C) Up-regulated SirT1 increases SRF binding to the 
promoter regions of SMC differentiation genes. ChIP assays were performed using 
antibodies against SirT1, SRF, or normal rabbit IgG, respectively, as described in 
online supplemental data. PCR amplifications of the non-CArG regions were included 
as additional control for specific promoter DNA enrichment.  The data presented here 
are mean±S.E.M. of four independent experiments. *P<0.05 (vs. control). 
Figure 7. SMC transcription factor gene expressions were positively and 
transcriptionally regulated by SirT1.  
(A) mRNA levels of SRF, MEF2c and myocd were significantly up-regulated by 
SirT1 over-expression. Total RNAs were harvested as described in Figure 5A. (B) 
SirT1 regulated the promoter activities of SMC transcription factor genes. Day 2~3 
differentiating ES cells were transfected with luciferase reporter plasmids pGL3-SRF-
Luc, pGL3-MEF2c-Luc or pGL3-Myocd-Luc (0.15μg/2.5×104 cells) together with 
pcDNA3.1-SirT1 or pcDNA3.1 (0.2μg/2.5×104 cells). pShuttle-LacZ 
(0.2μg/2.5×104cells) was included as control. Luciferase and β-galactosidase activity 
assays were detected 48 hours after transfection. The data presented here are 
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mean±S.E.M. of three to six independent experiments. *P<0.05 (vs. control). (C) 
SirT1 binds directly to the promoter regions of SRF, MEF2c and myocardin genes. 
ChIP assays were performed using antibodies against SirT1 or normal rabbit IgG, 
respectively, as described in online supplemental data. PCR amplifications of the 
adjacent regions were included as additional control for specific promoter DNA 
enrichment.  The data presented here are mean±S.E.M. of four independent 
experiments. *P<0.05 (vs. control). 
 
 







